Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances


  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain
    • Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France
    • Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea
  • Partners

    Partners